Artemis Investment Management LLP Buys 72,971 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Artemis Investment Management LLP lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 484.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,031 shares of the medical research company’s stock after buying an additional 72,971 shares during the quarter. Artemis Investment Management LLP’s holdings in Thermo Fisher Scientific were worth $43,804,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. One Charles Private Wealth Services LLC lifted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company’s stock valued at $260,000 after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Holderness Investments Co. boosted its position in shares of Thermo Fisher Scientific by 1.7% during the fourth quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company’s stock worth $664,000 after acquiring an additional 21 shares during the last quarter. Port Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company’s stock worth $721,000 after purchasing an additional 22 shares during the last quarter. Finally, Clark Capital Management Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company’s stock worth $2,312,000 after acquiring an additional 23 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMO. Royal Bank Of Canada reduced their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Scotiabank lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research note on Friday, April 25th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $604.05.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 0.3%

Shares of NYSE TMO opened at $412.02 on Friday. The firm has a market cap of $155.53 billion, a price-to-earnings ratio of 24.17, a price-to-earnings-growth ratio of 2.17 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company’s 50-day simple moving average is $410.11 and its 200-day simple moving average is $484.47. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the prior year, the firm earned $5.11 earnings per share. The business’s revenue was up .2% compared to the same quarter last year. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific’s payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.